Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions
Autoimmune Myelofibrosis and Cytopenia Development
Acta Haematol; 2017 Sep 2; Piatek, et al
Autoimmune myelofibrosis (AIMF) plays a role in the development of cytopenias in patients with autoimmune disorders, according to a small study involving 12 individuals. Improvement occurred with immunosuppressive therapy. Investigators conducted a single-institution, retrospective chart review of patients with AIMF, looking at clinical presentations, therapies, and outcomes. Among the results:
- All patients had detectable autoantibodies; most had concomitant autoimmune disorders.
- Immunosuppresive therapy led to complete response of cytopenias in 4 patients and partial response in 3.
- Partial response occurred in 1 patient post-splenectomy.
- No myeloproliferative neoplasms were seen during a median follow-up of ~6 years.
Piatek C, Vergara-Lluri M, Pullarkat V, et al. Autoimmune myelofibrosis: Clinical features, course, and outcome. Acta Haematol. 2017;138(3):129-137. doi:10.1159/000479103.
This Week's Must Reads
Must Reads in Hematologic Malignancies
Long-term ibrutinib data in older patients, Barr PM et al. Haematologica. 2018;103(9):1502-10
Prognostic Score System for Patients with PMF, J Clin Oncol; ePub 2017 Dec 9; Gugliemelli, et al
These Patients Are More Apt to Be Depressed, Ann Hematol; ePub 2017 Dec 7; Shreders, et al
Survival Length Shortest in These Patients with MF, Eur J Haematol; ePub 2017 Dec 11; Masarova, et al
The Value of Ruxolitinib Before and After AlloSCT, Blood; ePub 2017 Dec 7; Poulose, Malysz, et al